Date: 2026-04-03 Quarter: Q4 FY25 (Dec-2025) Market cap: ~$3.0B | EV/TTM Rev: 7.7x | Revenue growth: 81.4% YoY
Arcutis delivered a strong Q4 FY25 that exceeded my expectations on revenue, margins, and cash flow. Net product revenue of 127.5M(+8426.2M) ahead of schedule. The profitability inflection is now structurally confirmed: two consecutive GAAP profitable quarters, operating margin expanding from -10.6% to +14.2% YoY. FY2026 guidance was raised to 480 − 495M(+30510M. The thesis is intact and marginally strengthening. The single-molecule risk and ~2030 patent cliff remain the binding constraints on conviction.
Conviction: 3/5 (Hold / Watchlist — thesis intact, execution excellent, but single-product pharma risk and growth deceleration to ~30% cap conviction at current valuation)
| Criterion | Threshold | Actual | Pass/Fail |
|---|---|---|---|
| Revenue YoY growth | >30% | 81.4% (Q4 FY25) | PASS |
| Gross margin | >60% (>70% pref) | 91.0% | PASS |
| Revenue per quarter | >$50M | $129.5M | PASS |
| Data availability | 4+ quarters | 16 quarters | PASS |
| Share dilution | <10% annual | 2.6% (125.0M to 128.3M basic) | PASS |
| GAAP profitability trajectory | Improving/positive | Positive Q3-Q4 FY25, expanding | PASS |
All gates passed.
| Factor | Rating | Detail |
|---|---|---|
| Growth | Strong | 81.4% YoY Q4; FY25 full year +91%. Net product revenue +84% YoY, +31% QoQ. Sequential growth re-accelerated from +22.3% to +31.2% on net product revenue. |
| Trajectory | Decelerating (hyper to strong) | YoY growth normalizing from 91% (FY25) to ~30% (FY26 guide). QoQ sequential trend is re-accelerating, which partially offsets headline deceleration. Base effects, not demand weakness. |
| Margins | High | Gross 91.0% (stable 6 consecutive quarters >87%). Operating margin +14.2% (swing +24.8pp YoY). SBC flat ~$10M/qtr, declining as % of revenue. FCF margin 20.2%. |
| Dominance | Dominant (in niche) | #1 branded non-steroidal topical, 45% share across 3 FDA-approved indications. No competitor has that label breadth. AAD strong recommendation. 200x more potent than Pfizer's failed Eucrisa. |
| Valuation | Fair | EV/TTM Rev ~7.7x, EV/Fwd Rev ~5.9x, run-rate P/E ~43x. Growth-adjusted forward multiple 0.20. Fair for a newly profitable pharma growing 30%+ with 91% gross margins. |
| Special | Present | (1) Pediatric PsO PDUFA June 29, 2026. (2) Infant AD sNDA Q2 2026. (3) Management peak sales $2.6-3.5B vs Street $1.69B. (4) OCF inflection ahead of schedule. |
| | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | | | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---| | Revenue ($M) | 2.8 | 5.2 | 38.1 | 13.5 | 49.6 | 30.9 | 44.8 | 71.4 | 65.8 | 81.5 | 99.2 | 129.5 | | YoY % | -- | -- | -- | -- | 1671% | 494% | 17.6% | 429% | 32.7% | 164% | 121% | 81.4% | | QoQ % | -6.7% | 85.7% | 633% | -64.6% | 267% | -37.7% | 45.0% | 59.4% | -7.8% | 23.9% | 21.7% | 30.5% | | Net Prod Rev ($M) | -- | -- | -- | -- | -- | -- | -- | 69.4 | 63.8 | 79.5 | 97.2 | 127.5 | | Gross Margin % | 71.4% | 84.6% | 96.9% | 83.7% | 93.3% | 88.7% | 87.7% | 90.3% | 86.6% | 90.8% | 91.2% | 91.0% | | Op Margin % [GAAP] | -2725% | -1285% | -97% | -453% | -63.7% | -162% | -87.3% | -10.6% | -37.2% | -17.9% | +8.6% | +14.2% | | Net Margin % | -2861% | -1365% | -118% | -491% | -71.4% | -169% | -92.6% | -15.1% | -38.1% | -19.5% | +7.5% | +13.4% | | EPS (GAAP) | -1.31 | -1.16 | -0.73 | -0.58 | -0.32 | -0.42 | -0.33 | -0.09 | -0.20 | -0.13 | +0.06 | +0.14 | | Op Income (M)|−76.3|−66.8|−36.9|−61.2|−31.6|−50.1|−39.1|−7.6|−24.5|−14.6|+8.5|+18.4||FCF(M) | -80.4 | -66.6 | -44.0 | -56.2 | -31.6 | -45.2 | -34.7 | -0.7 | -31.0 | +0.3 | -1.8 | +26.2 | | SBC ($M) | 9.5 | 10.6 | 10.0 | 8.8 | 10.0 | 12.5 | 10.2 | 8.9 | 9.8 | 10.5 | 10.0 | 10.1 | | Shares (M, basic) | 61.2 | 61.4 | 61.7 | 92.9 | 111.0 | 123.5 | 124.3 | 125.0 | 126.0 | 127.0 | 132.9 | 128.3 |
| FY2023 | FY2024 | FY2025 | FY2026 Guide | |
|---|---|---|---|---|
| Net Product Revenue ($M) | -- | 166.5 | 372.1 | 480-495 |
| Total Revenue ($M) | 59.6 | 196.7 | 376.0 | -- |
| YoY Growth | -- | 230% | 91% | ~30% |
| OCF ($M) | -247.1 | -112.2 | -5.6 | Positive all quarters |
| SBC ($M) | 38.8 | 41.7 | 40.4 | -- |
Entering Q4 FY25, I expected:
| Metric | Expected | Actual | Verdict |
|---|---|---|---|
| Revenue | $120-124M | $129.5M | Beat (+$6-9M) |
| Net product revenue | $118-122M | $127.5M | Beat (+$6-9M) |
| QoQ growth (total) | 20-25% | 30.5% | Beat — re-acceleration |
| Gross margin | ~91% | 91.0% | In line |
| Operating margin | 10-13% | 14.2% | Beat |
| Operating income | $10-13M | $18.4M | Significant beat |
| Net income | $5-8M | $17.4M | Significant beat |
| OCF | ~$0-5M | +$26.2M | Massive beat |
| FY2026 guidance raise | $0-10M | +$25M (to $480-495M) | Beat |
| EPS (basic) | $0.04-0.06 | $0.14 | Significant beat |
Three things surprised me:
Sequential re-acceleration. Net product revenue QoQ growth of +31.2% reversed a two-quarter deceleration trend (Q2: +24.6%, Q3: +22.3%). This was driven by both demand (TRx volume) and improved pricing dynamics, not just seasonality. The re-acceleration signal is meaningful because it suggests the growth algorithm has not saturated.
OCF magnitude. +26.2Mvs.−1.8M in Q3. I expected the OCF inflection to begin in Q1 FY26, not Q4 FY25. Management's "ahead of schedule" framing is accurate. The quarterly swing of +$28M suggests the cost structure is now firmly below revenue capacity.
Guidance raise size. A 25Mmidpointraise(5.4510M annualized exceeding the 487.5Mmidpointby 22.5M, this guidance looks conservative. Management has established a beat-and-raise cadence.
What did NOT surprise me: gross margin stability (91%), continued SG&A leverage, flat SBC, modest dilution.
| Indicator | Current | Prior (Q3 FY25) | Direction | Signal |
|---|---|---|---|---|
| Weekly Rxs (4-wk rolling) | ~22,000 | ~18,500 (est.) | +99% YoY | Bullish |
| Commercial payer access | >80% single-step | -- | Expanding | Bullish |
| Medicaid access | >50% single-step | -- | Expanding | Bullish |
| Medicare Part D | ~33% coverage | -- | Weakest tier | Neutral |
| Branded NS market share | 45% | ~40% (est.) | Growing | Bullish |
| Derm sales reps | ~160 (+20% YoY) | ~133 | Expanding | Bullish |
| PC/peds pilot reps | ~30 (new) | 0 (Kowa) | Transition | Watch |
No bearish divergence detected. All demand indicators align with or exceed revenue growth. Revenue per prescription stable. GTN and pricing dynamics healthy.
Flag: Kowa-to-internal primary care transition first impacts Q1 FY26.
| Metric | Current (~Apr 2026) | 1Y Ago (est.) | Peer Context | Assessment |
|---|---|---|---|---|
| Market cap | ~$3.0B | ~$1.5B | -- | ~100% rally |
| EV | ~$2.9B | ~$1.4B | -- | -- |
| EV/TTM Revenue ($376M) | 7.7x | ~7x | Specialty pharma 3-5x; growth 6-10x | Fair-to-rich |
| EV/Fwd Revenue ($487.5M) | 5.9x | -- | -- | Attractive for 30%+ grower |
| EV/TTM Gross Profit ($339M) | 8.5x | -- | -- | Reasonable |
| P/E (Q4 annualized) | ~43x | N/A (loss) | Growth pharma 25-50x | Fair |
| Rule of 40 (Q4) | 101 | -- | >40 healthy | Exceptional |
Secular trend: Structural shift from TCS to non-steroidal topicals. AD market projected $29.9B by 2030 (9% CAGR). Multi-decade tailwind.
Platform vs. point solution: Point solution today. Platform emerging: 160-rep commercial infrastructure, pediatric expansion, ARQ-234 biologic pipeline, vitiligo/HS programs. Commercial engine is the platform.
TAM penetration: ~15-20% of management's $2.6-3.5B peak sales target.
Analysis by Atlas | 2026-04-03 | No position held